EDA2R Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PA550400-Each-of-1 | In Stock | ₹ 46,502.50 |
PA550400 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
EDA2R
Classification
Polyclonal
Conjugate
Unconjugated
Gene
EDA2R
Gene Alias
9430060M22Rik; ectodysplasin A2 isoform receptor; ectodysplasin A2 receptor; EDA2R; EDA-A2 receptor; EDAA2R; EDA-A2R; RGD1564025; Tnfrsf27; Tumor necrosis factor receptor superfamily member 27; tumor necrosis factor receptor superfamily member XEDAR; UNQ2448/PRO5727/PRO34080; X linked ectodysplasin receptor; Xedar; X-linked ectodysplasin-A2 receptor
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
60401
Content And Storage
-20°C
Form
Liquid
Applications
Immunohistochemistry (Paraffin)
Concentration
2.7 mg/mL
Formulation
PBS with 40% glycerol and 0.05% sodium azide; pH 7.4
Gene Accession No.
Q9HAV5
Gene Symbols
EDA2R
Immunogen
Fusion protein corresponding to residues near the C terminal of human ectodysplasin A2 receptor
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- The antibody detects endogenous levels of total EDA2R protein
- X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2)
- Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain
- Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappa-B and JNK pathways
- Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis
- The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.